The TRAIN-HEART consortium, funded by the European Commission (2019-2023), is made up to train a league of 15 promising fellows that harness novel insights in the pathogenesis of ischemic heart failure, study the therapeutic potential of existing RNA therapeutics and improve its efficacy by the design of novel drug delivery systems.


TRAIN-HEART brings together leading academic teams and (biotech) companies covering various disciplines ranging from fundamental research to clinical pharmacology and gene therapy to drug delivery applications, have teamed up in the European Union.

Research Programme

The TRAIN-HEART network aims to gain viable insight in the pathogenesis of ischemic heart failure which will serve as a basis for drug discovery and drug delivery efforts that aim to therapeutically target specific molecules and mechanisms within cardiomyocytes for the treatment of ischemic heart failure.  


If you have any questions you can fill in the form or mail us directly:


HFA Webinar: Next generation RNA therapeutics

This webinar is covered by highly esteemed cardiovascular researchers including Prof. Thomas Thum (Hannover Medical School) and Prof. Gianluigi Condorelli (Humanitas University Milan). They are also Principal Investigators in the TRAIN-HEART network, hosting 3 Early Stage Researchers.

Expected Outcome

The expected outcome is an improved understanding of:

  • How noncoding RNAs control biological functions of cardiovascular cells
  • How they can be used as biomarkers or therapeutic targets

Target Audience

Clinical and basic/translational professionals in the field of cardiology and RNA biology.

Learning Objectives

After watching this webinar, participants will be able to:

  • Understand the underlying mechanisms of how noncoding RNAs contribute to the cardiac remodelling process
  • Demonstrate the power of noncoding RNA modulation both for the diagnosis and therapy of heart failure

Watch the webinar recording HERE